BYSI News and Press, BeyondSpring Inc. From 11/17/20

BeyondSpring (BYSI): Q3 GAAP EPS of -$0.48 beats by $0.06.Cash and cash equivalents of $30.87M.Press Release For further details see: BeyondSpring EPS beats by $0.06

- Announced SEED Therapeutics Inc.(“SEED”)’s collaboration with Eli Lilly and Company(“Lilly”) NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a globa...

BeyondSpring (BYSI) +5% in premarket after announcing topline data from its PROTECTIVE-2 Phase 3 study showing that plinabulin in combination with Amgen's Neulasta (pegfilgrastim) met the primary endpoint with statistically significant improvement in the rate of prevention of G...

Study met primary endpoint showing statistically significant improvement in rate of prevention of G rade 4 neutropenia in C ycle 1, p = 0.0015 Study met statistically significant improvement in key secondary endpoints, including DS...

NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medi...

BeyondSpring's (BYSI) subsidiary Seed Therapeutics, has entered into a research collaboration and license agreement with Eli Lilly (LLY) to discover and develop new chemical entities for potential therapeutic benefit through targeted protein degradation.Seed Therapeutics utilizes “...

Beyond Spring (BYSI) subsidiary Seed Therapeutics inks a research collaboration and license agreement with Eli Lilly (LLY) aimed at discovering and developing novel molecules that provide therapeutic benefit via targeted protein degradation.Seed has pioneered a strategy called “molecul...

- Seed Therapeutics to Use Proprietary “Molecular Glue” Protein Degradation Technology to Develop Potential New Medicines - NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Seed Therapeutics (“the Company”), a global research company and subsidiary of Be...

NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Seed Therapeutics Inc. (the “Company” or “Seed Therapeutics”), a global research company and BeyondSpring subsidiary focused on harnessing and engineering “molecular glue,” a targeted protein degradation (...

NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology and chemotherapy-induced neutropenia therapies, announc...